All In Biotech

Drug Trial Radar · NCT05274269

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-responsive CFTR Mutation

Last checked: Nov 19, 2026Latest source record: Aug 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 307 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

307

Actual

Start

May 9, 2022

Primary completion

Jul 5, 2023

Study completion Jul 5, 2023

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Mar 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the efficacy, pharmacodynamics (PD) and safety of ELX/TEZ/IVA in participants 6 years of age and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.

Conditions

  • Cystic Fibrosis

Interventions

  • ELX/TEZ/IVADrug

    Fixed-dose combination (FDC) tablets for oral administration.

  • IVADrug

    Tablet for oral administration.

  • Placebo (matched to ELX/TEZ/IVA)Other

    Placebo matched to ELX/TEZ/IVA for oral administration.

  • Placebo (matched to IVA)Other

    Placebo matched to IVA for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)Time frame: From Baseline Through Week 24

Locations

90 sites in 15 countries. Site status is shown where the registry gives one.

  • Medizinische Universität Innsbruck

    Innsbruck, Austria

  • Cliniques Universitaires de Bruxelles Hopital Erasme

    Brussels, Belgium

  • Universitair Ziekenhuis Brussel - Campus Jette

    Brussels, Belgium

  • Universitair Ziekenhuis Antwerpen (UZA) - Antwerp University Hospital

    Edegem, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, Belgium

  • Stollery Children's Hospital

    Edmonton, Canada

  • Centre Hospitalier de l'Universite de Montreal (CHUM) Hotel-Dieu

    Montreal, Canada

  • McGill University Health Centre, Glen Site, Montreal Children's Hospital

    Montreal, Canada

  • The Hospital for Sick Children

    Toronto, Canada

  • British Columbia Children's Hospital

    Vancouver, Canada

  • St. Paul's Hospital

    Vancouver, Canada

  • Klinika Detskych Infekcnich Nemoci

    Brno, Czechia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • CHU Lyon - Hopital Femme Mere-Enfant

    Bron, France

  • Centre Hospitalier Intercommunal Creteil

    Créteil, France

  • Institut Cœur Poumon, CHU de Lille

    Lille, France

  • CHU Marseille - Hopital Nord

    Marseille, France

  • Hopital Arnaud de Villeneuve

    Montpellier, France

  • Centre Hospitalier Universitaire De Nantes - G. R. Laennec

    Nantes, France

  • Centre Hospitalier Universitaire (CHU) de Nice - Hopital Pasteur

    Nice, France

  • Hopital Cochin

    Paris, France

  • Hopital Necker, Enfants Malades

    Paris, France

  • Hopital Robert Debre

    Paris, France

  • Hopital Haut-Leveque - CRCM Adulte

    Pessac, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Centre Hospitalier Universitaire De Reims, Hopital Sebastopol

    Reims, France

  • CHU de Rennes - Hôpital Sud

    Rennes, France

  • Centre de Perharidy

    Roscoff, France

  • CHU de Toulouse - Hopital Larre

    Toulouse, France

  • Hopital Bretonneau

    Tours, France

  • Charite Paediatric Pulmonology Department

    Berlin, Germany

  • Universitaetsklinkum Koeln, CF-Studienzentrum

    Cologne, Germany

  • Friedrich-Alexander University of Erlangen-Nuremberg, University Children's Hospital

    Erlangen, Germany

  • Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen

    Essen, Germany

  • Johann Wolfgang Goethe University

    Frankfurt, Germany

  • Justus-Liebig-Universität Gießen Zentrum für Kinderheilkunde und Jugendmedizin

    Giessen, Germany

  • Universitätsklinikum Halle (Saale) / Universitätsklinik und Poliklinik für Innere Medizin, Schwerpunkt Pneumologie

    Halle, Germany

  • Hannover Medical School

    Hanover, Germany

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.